Wide Open Agriculture Limited (ASX: WOA), founded in 2015 and headquartered in Kew, Victoria, is an Australian food technology company focused on sustainable plant-based protein solutions. The company’s flagship product, Buntine Protein, is a high-protein, non-GMO lupin isolate designed for use in dairy alternatives, meat substitutes, and functional food applications. Manufactured through a patented, chemical-free process, Buntine Protein offers a nutritionally superior and environmentally sustainable alternative to conventional plant-based proteins. With rising demand for sustainable protein solutions, WOA is positioning itself as a leader in the global plant-based food industry, driving innovation in clean-label, high-protein alternatives.
China’s plant-based protein market is experiencing rapid growth, driven by changing dietary habits, government health initiatives, and increasing demand for sustainable food sources. Market projections indicate that the sector will grow to US$12.1 billion by 2030, with a compound annual growth rate (CAGR) of 12.4%.
Soy protein remains the dominant source of plant-based protein in China, but with 83% of global soybean crops being genetically modified (GMO), there is growing demand for non-GMO, high-protein alternatives. WOA’s lupin protein isolate, derived from Western Australian sweet lupins, meets this demand by offering a clean-label, highly digestible, and complete protein source without the concerns associated with soy-based or animal-derived proteins.
WOA is actively working with local food manufacturers and distributors to develop lupin-based products tailored to Chinese consumer preferences, including plant-based protein powders, lupin-based dairy alternatives (milk, yoghurt, ice cream), and alternative tofu products made from lupins instead of soy.
By collaborating with Chinese food companies, WOA aims to secure long-term supply agreements and establish a foothold in Asia’s fast-growing plant-based protein market.
China’s Healthy China 2030 initiative is driving demand for functional plant-based proteins, as the government seeks to reduce chronic disease risks through improved nutrition. Clinical studies have shown that daily consumption of lupin protein can lower LDL cholesterol and improve lipid profiles, making it an ideal ingredient for health-focused food applications.
With cardiovascular disease accounting for 46.7% of deaths in rural China and 44.3% in urban areas, the Chinese government is actively encouraging plant-based dietary shifts. WOA’s non-GMO, heart-healthy lupin protein aligns with this initiative, providing a scientifically backed, premium plant protein alternative for health-conscious consumers.
Following regulatory approval, WOA is focused on accelerating market entry through strategic partnerships, product development, and consumer education. The company is distributing product samples to Chinese food and beverage companies to test integration into existing food formulations while conducting product trials with local manufacturers to ensure taste and texture meet Chinese consumer expectations. In parallel, WOA is advancing discussions with key distributors across China and Southeast Asia, with the goal of launching initial commercial sales in 2025. The company’s expansion into China represents a major milestone, reinforcing its long-term vision of global leadership in sustainable plant-based protein ingredients.
WOA’s successful regulatory approval in China places the company in a strong position to capitalise on growing global demand for plant-based protein. With a scientifically validated product, a patented chemical-free production process, and expanding distribution networks, WOA is emerging as a high-growth player in the sustainable food industry.
As the company progresses toward commercial production and large-scale supply agreements, investors will be closely watching for market penetration updates, new distribution deals, and further regulatory approvals in key international markets. With China’s plant-based food sector accelerating, WOA’s entry into the market could drive significant revenue growth and long-term shareholder value.
Chifley Tower, 2 Chifley Square,
Sydney NSW 2000
1300 854 151
© 2023 KOSEC | Kodari Securities Pty Ltd | ABN 90 147 963 755 | FSG | Terms & Conditions | Disclaimer & Legal
© 2023 KOSEC | Kodari Securities Pty Ltd
ABN 90 147 963 755
KOSEC - Kodari Securities does not provide any investment advice, nor is anything mentioned an offer to sell, or a solicitation of an offer to buy any security or other instrument. Anything discussed is for informational purposes only and does not address the circumstances or needs of any particular individual or entity. Investing in the stock market is high risk. Under no circumstances should investments be based solely on the information provided. We do not guarantee the security or completeness of information on this website and are not held liable. Kodari Securities PTY Ltd trading as KOSEC is a corporate authorized representative (AFSL no.246638) which is regulated by the Australian securities and investment commission (ASIC).